Work

In the Phase 3 Boreas Trial, Baseline Blood Eosinophils and Baseline Fractional Exhaled Nitric Oxide Levels Predict the Response to Dupilumab in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Year: 2024

Type: conference-abstract

DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6620

Authors: S. Christenson, N.A. Hanania, S.P. Bhatt, M. Bafadhel, K.F. Rabe, C.F. Vogelmeier, A. Papi, D. Singh, E. Laws, M.C. Nivens, A. Bansal, X. Lu, D. Bauer, J. Maloney, L.B. Robinson, R.M. Abdulai

Institutions: University of California, San Francisco, Baylor College of Medicine, University of Alabama at Birmingham, King's College London, German Center for Lung Research, LungenClinic Grosshansdorf, Philipps University of Marburg, University of Ferrara, University of Manchester, Manchester University NHS Foundation Trust, Sanofi (United States), Regeneron (United States)

Language: English

Topic: Chronic Obstructive Pulmonary Disease (COPD) Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4396516562

Cites:

Cited by: 2

Related to: 10